Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-803 combination immunotherapy in checkpoint inhibitor-experienced solid tumors
NCT03228667Phase 2Active, not recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Dec 2018
- Primary completion
- Aug 2029
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), urothelial carcinoma (UC), head and neck squamous cell carcinoma (HNSCC), Merkel cell carcinoma (MCC), sponsored by ImmunityBio, Inc.. Started Dec 2018; status: active, not recruiting.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)urothelial carcinoma (UC)head and neck squamous cell carcinoma (HNSCC)Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT03228667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03228667.